ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Coronavirus

Fujifilm to seek Avigan approval for COVID as early as October

Trials show patients' symptoms improve nearly two days sooner with antiviral

Avigan, also known by its generic name favipiravir, has already been used as an anti-influenza medication in Japan.   © Reuters

TOKYO (Kyodo) -- Fujifilm Holdings Corp. said Wednesday it will seek regulatory approval as early as October for using its antivirus drug Avigan to treat patients infected with the novel coronavirus as clinical tests have shown efficacy in easing symptoms.

According to analysis of data on 156 patients without severe symptoms, Fujifilm found those administered with Avigan show improvement after 11.9 days, shorter than the 14.7 days for those in a placebo group.

If approved, the drug, also known as favipiravir, would be the third treatment drug for COVID-19, the respiratory disease caused by the virus.

Fujifilm Toyama Chemical Co., a subsidiary of Fujifilm Holdings, began clinical trials in March. It faced difficulty in securing enough data due to a downtrend in the number of coronavirus cases and the tests ended later than initially expected.

Fujifilm said it will continue with its detailed analysis of the data gathered during the study before filing its application for approval.

Former Prime Minister Shinzo Abe had expressed hope to have the drug approved in May but a Japanese university's interim report, released in mid-May, did not show any clear efficacy of Avigan against COVID-19.

In Japan, the antiviral drug remdesivir developed by U.S. firm Gilead Sciences Inc. was given the green light in May, followed by the steroid drug dexamethasone.

The number of coronavirus cases in the country has reached 80,500, including about 700 from the Diamond Princess cruise ship that was quarantined in the port of Yokohama in February. The death toll has topped 1,500.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more